InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: dmsrz8 post# 36116

Wednesday, 02/17/2021 3:50:58 PM

Wednesday, February 17, 2021 3:50:58 PM

Post# of 44690

You clearly don’t understand statistical power. The point that it DID show significance on such a small number is not a problem, rather that with more people it is almost likely to become even more statistically significant


A p value of .05 means that it has a 1 in 20 chance of being achieved randomly. So if you have a bunch of secondary endpoints and you slice and dice it into many subgroups, you'll end up with hundreds of possible scenarios. For every 100 scenarios, you'll end up with an average of 5 of them as having a p value of .05 through sheer randomness. This is why scientists don't care about one subset achieving one secondary endpoint. Any trial can have its data massaged to appear good at a few places. Primary endpoint is what scientists care about. RLFTF's trial failed in its primary endpoint. Not to mention more people dying in the treatment arm.......